With Takeda’s £46 billion acquisition of Shire, it’s been a busy year for pharma M&A – and according to analysts Datamonitor, the specialist biotechs Nektar, BioMarin and Alnylam are the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback